A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants with Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2D)

Change in HbA1c from baseline at Week 30

Change in HbA1c from baseline at Week 30, Percentage of participants with HbA1c < 5.7%, ≤ 6.5%, and < 7.0% at Week 30, Change in fasting plasma glucose from baseline at Week 30, Percent (%) change in body weight from baseline at Week 30, Absolute change in body weight (kg) from baseline at Week 30, Percentage of participants who achieve ≥ 5%, ≥ 10%, or ≥ 15% body weight reduction at Week 30, Incidence of AEs, AESIs, and SAEs, Number of participants with documented hypoglycemia (Level 1, 2, or 3 per ADA 2024), Change in safety laboratory values and vital signs, Change in ECG parameters, Plasma concentrations of RO7795081

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Hungary, Poland, Spain